{"links":{"feed":"https://www.erudio.com/reports/lotis-9-nct05144009/feed.json","html":"https://www.erudio.com/reports/lotis-9-nct05144009","json":"https://www.erudio.com/reports/lotis-9-nct05144009.json","markdown":"https://www.erudio.com/reports/lotis-9-nct05144009.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"lotis-9-nct05144009"}},"request":"https://www.erudio.com/contact?report=lotis-9-nct05144009"},"offer":{"cited_clinicians":2,"cited_commentary_sources":10,"verified_hcp_statements":49,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":6},"for_sale":false,"one_off_usd":null,"not_for_sale":{"note":"This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it; a later edition that reaches the minimum is for sale at its normal price.","contact":"https://www.erudio.com/contact?report=lotis-9-nct05144009","email":"hello@erudio.com"},"purchase":{"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=lotis-9-nct05144009","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/lotis-9-nct05144009","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 49 verified statements · 11 from 2 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":null,"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-22T20:06:05.303304Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":4,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":3,"title":"Primary endpoint: CR Rate"},{"claim_count":1,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":1,"title":"Primary endpoint: Cohort B: Percentage of Participants Who Completed 4 Cycles of Treatment"},{"claim_count":7,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":15,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":7,"title":"Population and setting"},{"claim_count":8,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":14,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":5,"title":"Safety and tolerability"},{"claim_count":9,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":5,"title":"Design and conduct"},{"claim_count":3,"coverage":"discussed","id":"A1","source_count":2,"title":"Off-trial boundaries and transparent reporting"},{"claim_count":3,"coverage":"discussed","id":"A2","source_count":1,"title":"Organ reserve and supportive-care requirements"},{"claim_count":5,"coverage":"discussed","id":"A3","source_count":1,"title":"Treatment burden and patient-centered selection across alternatives"},{"claim_count":4,"coverage":"discussed","id":"A4","source_count":2,"title":"Broader drug adoption and accelerated-approval confidence"},{"claim_count":1,"coverage":"discussed","id":"A5","source_count":1,"title":"Long-term expectations for contemporary combinations"}],"counts":{"beyond_population_findings":3,"beyond_population_statements":6,"cited_clinicians":2,"cited_clinicians_by_role":{"physician":1,"physician, Medical oncology":1},"cited_physicians":2,"cited_sources":13,"claims_by_expression_type":{"comparison":3,"experience":2,"interpretation":8,"opinion":12,"primary_context":12,"question":1,"restatement":9,"uncertainty":1,"unspecified":1},"claims_by_kind":{"protocol_statement":8,"publication_statement":4,"source_observation":37},"clinician_statements":11,"evidence_units":25,"findings":8,"organisational_accounts":1,"people_cited":7,"people_identity_verified":6,"people_total":7,"screened_sources":46,"verified_claims":49},"findings_index":[{"cited_clinicians":0,"id":"F1","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":7,"views":4},"limitations":3,"links":{"context":0,"support":11},"ma_question":true,"named_voices":2,"passages":5,"sources":5,"sources_by_kind":{"commentary":4,"publication":1}},"title":"LOTIS-9: speakers question AE attribution; one relays trial-only advice","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-e96e1f07ad845e6d797f","claim-84a50fbe26c378b64088"],"clause":"one relays trial-only advice","holders":1},"cited_claim_ids":["claim-60d2a6a3bd29d9a1adcd","claim-74a647aa8561f6494156"],"clinicians":false,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"11 statements from 2 speakers in 5 sources","holder_line":"2 of the 2 named speakers in this finding hold this view; 1 of them holds its caveat, “one relays trial-only advice”"},{"cited_clinicians":0,"id":"F2","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":3},"limitations":2,"links":{"context":0,"support":3},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Frailty and chemo-free care: why a speaker still stresses supportive care","title_holders":{"cited_claim_ids":["claim-803a26a64f937ad66203","claim-457907990e8a3614ea90"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"3 statements from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view"},{"cited_clinicians":0,"id":"F3","structure":{"claims":6,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":4,"views":1},"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":1,"passages":2,"sources":2,"sources_by_kind":{"commentary":1,"publication":1}},"title":"LOTIS-9 CRs: a speaker questions value vs R-mini-CHOP despite differing populations","title_holders":{"cited_claim_ids":["claim-840e5e7295e9427c926e"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"6 statements from 1 speaker in 2 sources","holder_line":"The one named speaker in this finding holds this view"},{"cited_clinicians":1,"id":"F4","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":2,"views":5},"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":2,"passages":4,"sources":4,"sources_by_kind":{"commentary":1,"media":3}},"title":"LOTIS-9: speakers welcome testing; a clinician ties an RCT to durable responses","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-ddbe55eb9d764bbdf33a"],"clause":"a clinician ties an RCT to durable responses","holders":1},"cited_claim_ids":["claim-3e9adfed3a842cb776fd","claim-1e1f5becec728061fc88","claim-153113ecf663cb0e4529","claim-7a8679f723fa248ecaf7"],"clinicians":false,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"10 statements from 2 speakers in 4 sources, 3 of them podcasts or videos","holder_line":"2 of the 2 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician ties an RCT to durable responses”"},{"cited_clinicians":0,"id":"F5","structure":{"claims":6,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":2,"views":3},"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":1,"passages":2,"sources":2,"sources_by_kind":{"commentary":1,"publication":1}},"title":"Older/unfit frontline DLBCL: a speaker highlights activity, not proof of superiority","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-49646f5784f926775846"],"clause":"not proof of superiority","holders":1},"cited_claim_ids":["claim-5a4824a2ab8438008bac"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"6 statements from 1 speaker in 2 sources","holder_line":"The one named speaker in this finding holds this view; 1 of them holds its caveat, “not proof of superiority”"},{"cited_clinicians":1,"id":"F6","population":"beyond","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":2,"questions":0,"restated":0,"views":3},"limitations":3,"links":{"context":2,"support":5},"ma_question":true,"named_voices":3,"passages":4,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Loncastuximab Tesirine: what speakers say","evidence_line":"5 statements from 3 speakers in 2 sources"},{"cited_clinicians":0,"id":"F7","population":"beyond","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":1},"limitations":2,"links":{"context":0,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Frailty trials: why a speaker seeks power for both efficacy and toxicity","title_holders":{"cited_claim_ids":["claim-a616b0fcb594ced5ecce"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"1 statement from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view"},{"cited_clinicians":0,"id":"F8","population":"beyond","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":1},"limitations":2,"links":{"context":1,"support":1},"ma_question":false,"named_voices":0,"passages":2,"sources":1,"sources_by_kind":{"media":1}},"title":"Contemporary combinations: why a speaker sees possible future standards","title_holders":{"cited_claim_ids":["claim-ca57a0756c7825c53f65"],"clinicians":false,"holders":0,"speakers":0,"view":"reading"},"evidence_line":"1 statement in 1 source, a podcast or video","holder_line":"No named speaker is counted in this finding: its title's view comes from speakers the source does not name"}],"open_question":{"basis":"From findings F1 (11 statements from 2 speakers in 5 sources) and F4 (10 statements from 2 speakers in 4 sources)","cited_claim_ids":["claim-84a50fbe26c378b64088","claim-717cd59eacce7ca40dd6","claim-362aa828fc8e3b974699","claim-60d2a6a3bd29d9a1adcd","claim-e6bc7e0990d8052df3f6","claim-74a647aa8561f6494156","claim-c62a030712d67670f0fa","claim-defcd1f0c95cfc87539e","claim-c527bbeb2846c5efeb68","claim-ba8c9374c6077de10b00","claim-1e1f5becec728061fc88","claim-9fc8f7ed214db8bd2db1","claim-2701bf5949d14549326b","claim-aec8f03fbdb3a127d581","claim-ddbe55eb9d764bbdf33a"],"finding_ids":["F1","F4"],"question":"What do clinicians say would clarify whether pulmonary deaths in LOTIS-9 reflected comorbidities alone or also toxicity from loncastuximab tesirine plus rituximab as chemotherapy replacement in previously untreated unfit or frail DLBCL?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One author questions a comorbidity-only explanation of harm and relays limits on off-trial use"},{"id":"section-2","level":2,"title":"One author argues for attention to organ reserve and supportive care despite chemotherapy avoidance"},{"id":"section-3","level":2,"title":"One author asks whether the responses are meaningful against an R-mini-CHOP benchmark"},{"id":"section-4","level":2,"title":"One interview speaker welcomed the investigational question, with comparative validation conditional on promise"},{"id":"section-5","level":2,"title":"One X account welcomes further study of alternatives but rejects a response-rate hierarchy"},{"id":"section-6","level":2,"title":"Beyond the trial population"},{"id":"section-7","level":3,"title":"One X account defers use and raises possible withdrawal; another asks for randomized confirmation"},{"id":"section-8","level":3,"title":"One X account calls for dedicated frailty-focused trials with efficacy and toxicity power"},{"id":"section-9","level":3,"title":"On one episode, contemporary combinations were described as possible future standards"},{"id":"section-10","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, sequential, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F5","shared_claims":1}],"id":"T1","label":"Primary endpoint: CR Rate"},{"findings":[{"id":"F3","shared_claims":1}],"id":"T2","label":"Primary endpoint: Cohort B: Percentage of Participants Who Completed 4 Cycles of Treatment"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":8},{"id":"F5","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":4},{"id":"F5","shared_claims":3}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":8},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":2},{"id":"F5","shared_claims":2}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":3}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-22T20:06:05.303304Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-22T20:19:39Z","record_hash":"7b436f86600507f97ec20cee3fa4869e5033a19bc441eb03d6303b5e85d63b82","release_hash":"a30a17c1d1b2c26501bb9a17adf1c8843a249bc383edd244bca6559d62f2f382","report_id":"erudio-nct05144009","run_id":"30f3555c-d9e8-4aba-8e7e-fda5e543ba1e","schema_version":"5.0","slug":"lotis-9-nct05144009","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"One speaker reads LOTIS-9 as a warning that avoiding chemotherapy does not remove toxicity, citing pulmonary deaths while questioning their reported attribution to comorbidities rather than drug effects. Their concern turns on cardiopulmonary reserve that functional frailty scores may not capture. Their comparison with R-mini-CHOP acknowledges different populations, leaving relative benefit unresolved. Another speaker calls for frailty-specific trials powered to assess benefit and toxicity; the discussion does not establish that treatment caused the deaths.","examples":[],"meta_description":"46 sources screened · 49 verified statements (11 from clinicians verified by NPI or staff page) from 13 sources · 8 findings. Updated Nov 22, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-22T20:19:39Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":46},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","Not yet captured in this edition: a remark on trial discontinuation in previously untreated unfit or frail diffuse large B-cell lymphoma; a view on frontline polatuzumab-containing treatment, its approval basis, comparative efficacy, and follow-up limitations; a view on pretreatment assessment, treatment urgency and systemic versus local therapy in newly diagnosed diffuse large B-cell lymphoma.","3 passages in 1 source used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","39 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 10 sources about other trials or topics are not included.","The sources reviewed for this edition are a selective set of public discussions, not a representative sample of HCP opinion. Multiple sources or posts must not be interpreted as multiple independent clinicians.","Discussion that did not name LOTIS-9 or used different wording may be missing. Some relevant podcast passages, including discussion of a frontline polatuzumab-containing regimen, were not fully assessed.","Not all podcast statements can be assigned to named participants. The long-term treatment-landscape expectation therefore remains attributed to the episode rather than to a named speaker.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The July 2023 safety-hold discussion, 2022 rationale interviews and 2026 commentary describe different moments. Dates alone do not establish a change of mind or direct disagreement.","ClinicalTrials.gov first posted results for the trial on 30 January 2025. The cited commentary spans 2022–2026 rather than wholly predating that posting.","Cross-trial benchmarks and the shared-slide treatment snapshot do not establish comparative efficacy. The discrepant LOTIS-9 figures in the slide account and publication are not explained by the sources.","Reported adverse events and clinical anecdotes do not establish treatment causality. The prophylaxis pattern does not establish prevention of fatal events, and the brief clinic reply does not identify an adverse-event type or patient population."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":1,"publication":1,"registry":2,"regulatory":0,"x_thread":5,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":10,"context":1,"methods":2},"count":13,"evidence_window":{"end":"2026-10-28","start":"2022-07-06"},"retrieval_snapshot":"2026-11-22T19:11:46.174156Z","timeline":[{"count":1,"week":"2022-W27"},{"count":1,"week":"2022-W44"},{"count":1,"week":"2022-W50"},{"count":1,"week":"2023-W26"},{"count":1,"week":"2023-W28"},{"count":1,"week":"2023-W29"},{"count":1,"week":"2023-W32"},{"count":1,"week":"2026-W37"},{"count":2,"week":"2026-W44"}],"undated_sources":3},"quote_policies":[{"id":"clinicaltrials:NCT05144009:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05144009:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05144009:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05144009:protocol:1","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05144009:sap:2","quote_policy":"short_quote_link_out"},{"id":"pubmed:42879743","quote_policy":"short_quote_link_out"},{"id":"openfda:af54af12-3edf-4301-8bc5-0446bc813c1d:20261111","quote_policy":"short_quote_link_out"},{"id":"openfda:f941fc61-f7a3-4e4a-ab7c-87c1667fa05b:20261002","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7521029932727144448","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:363f97","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1550064019217780737:002cac43-4879-4935-b0fc-c2f977bbea54","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1550239531881955328:8119e64b-2871-4560-87ea-9d63167646ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1574715775029776384:f67422ad-a599-4065-962f-be4d9310c1be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1574716821240156161:e445813c-4447-47e9-b963-e3dc875863ec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1575249581562073089:7409d478-2982-4978-a4e5-e93c9dc09484","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1602064432313630721:ed6a87fc-059a-409d-b453-1f9940726151","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1604054151490686978:0fcb905a-ad3e-462d-9a79-f26a8a7e04ac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1678720982335250432:46381a43-4853-4ec9-bb8a-f203c910eae0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1678721034286145536:5c373de5-587a-4d46-a8da-582f6f42e923","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1678721101906468864:dbfe03e8-59f8-4760-ab00-43bc2632819f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1678721905161826304:16923ed7-96ac-430f-9f9b-02527ffa88d6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1678722828953169920:d5c7d9ab-86e0-47a5-957c-12f5cd883f6f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1678740125423992833:f1d88bd0-3e4b-4934-a2f5-d75323d3e605","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1678744776399818753:56eb16b5-a9cf-436f-a201-bcfe5809010c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1678752655248617472:432c981c-e7f9-430e-9475-60ba94cd418d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1678872191281283072:ce3ef0bb-689b-46fd-b094-3db9d90ec954","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1678904704988856326:abd5f8cc-694c-42ea-b8c0-ba0fc5b038aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1679072435654516738:eb132027-cc38-4e15-b94e-2cfcf60d1e85","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1679129138131501059:52839b82-1fdf-4185-92c1-a6a4d917f7e9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1679146799788093441:ab67f63e-e247-45d7-91c7-a30b071ddb5f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1679199765169336339:6e285608-b451-4023-86f9-fe0c81652329","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1680230994891210756:19ea2f49-75a9-44b6-af0f-1d60c70c5ed0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1681121784630763524:ffae51d1-743c-496e-b551-8fce1b4b319e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1681408832696893441:255f8e4b-b145-4ffe-96a6-d0ab58d4cba7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1682119549766778880:37fc0afb-c986-4f33-9ebb-834685497554","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1682122707859587073:f957d463-ac6d-4734-9661-40c0c14f41a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1682125122449158151:8b6470df-cd97-4e28-8af6-7d027ac8ba2e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1682147641914806273:99240814-d982-4a2f-a380-f10a1cd9e035","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1682251030984273925:f280fa12-e897-4057-996c-4db92a25f6a7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1682353587932868608:efd6fa11-b142-4573-9166-06773662c4fb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1682397767761526785:66b13c6d-ab5f-4dd9-ba1f-7498a69457fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1682421228915634179:0a0f0b13-4bfd-4b7f-8ff0-d2c61a62efb4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1682473516463947783:cda6d351-8f1e-4392-ac2d-0bb9a0f22da2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1683439384262057987:339dfb69-66c5-452a-a090-ccb8cd0158d9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1684126414688116738:5bf04ac3-0b98-493f-8fb0-16f679c23e86","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1684685390660124672:9ea476a5-8d29-4743-a9db-9a9b4444cb4c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1689776280655511555:2e2f5cf0-96e1-479a-a584-5b08ec2d896e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1690465793660637184:972d10f9-0e8a-4a7f-8642-c483f0370535","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098506281103524279:28141301-5147-41eb-b6b4-40a1cb1776ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114814367204041152:0ff90e49-2bd0-4f78-a8d3-2b4b1406a5ce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115264322024939751:a1fe6596-406e-4328-b3df-00bc949f4d5f","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:o8moZZlL5_I","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:uNQSB6HCCd4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:vSvCDNvNe_I","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":41,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":46},"count":46,"evidence_window":{"end":"2026-10-28","start":"2022-07-06"},"retrieval_snapshot":"2026-11-22T19:11:46.174156Z","timeline":[{"count":1,"week":"2022-W27"},{"count":2,"week":"2022-W29"},{"count":3,"week":"2022-W39"},{"count":1,"week":"2022-W44"},{"count":1,"week":"2022-W49"},{"count":2,"week":"2022-W50"},{"count":1,"week":"2023-W26"},{"count":15,"week":"2023-W28"},{"count":11,"week":"2023-W29"},{"count":3,"week":"2023-W30"},{"count":2,"week":"2023-W32"},{"count":1,"week":"2026-W37"},{"count":3,"week":"2026-W44"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":11,"other":0,"podcast":1,"publication":4,"registry":9,"regulatory":0,"x_thread":15,"x_video":0,"youtube":9}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Zynlonta"],"label":"loncastuximab tesirine","slug":"loncastuximab-tesirine"},{"brand_names":["Rituxan"],"label":"rituximab","slug":"rituximab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Diffuse large B-cell lymphoma","slug":"diffuse-large-b-cell-lymphoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"LOTIS-9","aliases":["LOTIS-9","A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)","A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)"],"brief_title":"A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Diffuse Large B-cell Lymphoma"],"display_condition":"previously untreated unfit/frail diffuse large B-cell lymphoma","display_interventions":[["loncastuximab tesirine","rituximab"]],"enrollment":{"count":41,"type":"ACTUAL"},"interventions":[{"name":"Loncastuximab Tesirine","synonyms":["Zynlonta","ADCT-402"],"type":"DRUG"},{"name":"Rituximab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05144009","official_title":"A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)","overall_status":"TERMINATED","phase":["PHASE2"],"primary_completion_date":{"date":"2024-01-22","type":"ACTUAL"},"primary_endpoints":[{"description":"Defined as percentage of participants with a best overall response (BOR) of CR as determined by the Investigator according to the 2014 Lugano Classification criteria. CR was defined as achieving: * Complete metabolic response for positron emission tomography (PET)-computed tomography (CT) OR * Complete radiologic response (target node regress to \\<1.5 cm, no non-measured lesions, no organ enlargement, no new lesions and normal bone marrow morphology) for CT if disease was not fluorodeoxyglucose (FDG)-avid at baseline.","measure":"CR Rate","timeFrame":"Up to a maximum of 17.1 months"},{"description":"Defined by the number of participants who completed a total of 4 cycles of therapy divided by the total number of participants \\* 100.","measure":"Cohort B: Percentage of Participants Who Completed 4 Cycles of Treatment","timeFrame":"Up to 12 weeks (3 week cycle length)"}],"registered_date":{"date":"2021-12-03","type":"ACTUAL"},"registry_last_updated":"2025-01-30","registry_url":"https://clinicaltrials.gov/study/NCT05144009","short_name":"LOTIS-9","short_name_basis":"registry_acronym","sponsor":"ADC Therapeutics S.A.","start_date":{"date":"2022-06-21","type":"ACTUAL"},"study_design":"interventional, non randomized, sequential, phase2","study_ids":[{"id":"ADCT-402-203","type":"sponsor_study_id"},{"id":"2021-005312-57","type":"eudract_number"},{"id":"2022-501601-12-00","type":"ctis"}],"study_type":"INTERVENTIONAL"}}}